Targeted Healthcare Services based on HPV Strain Prevalence

Our approach ensures targeted screening programs aligned with specific strains prevalent by community. The process a digitized LBC-PAP with AI for screening reducing costs by 70%. Its followed by Molecular diagnosis to ensure the HPV type. This precision-driven strategy optimizes resource utilization and fosters more impactful population health outcomes.

Dr. Ranjani Chakravarthy, MD

In the landscape of cervical cancer screening, current approaches are often driven by vaccine adequacy, overlooking the diverse prevalence of HPV strains by community. Our solution leverages digitized LBC-PAP with AI, reducing screening costs by 70%. Molecular diagnosis follows, ensuring accurate HPV typing. This precision-driven strategy maximizes resource utilization for impactful population health outcomes.

Our solution is crafted to serve women globally, particularly those in resource-constrained and underserved communities. Cervical cancer disproportionately affects women in these regions, and our aim is to bridge the gap in access to accurate and affordable screening, diagnosis, and subsequent treatment.

While vaccination is considered to be the major response to HPV, we have observed during our studies that much of the population is beyond the critical age of vaccination and need to be screened. Moreover, the effectiveness of vaccines may not be suited to the community due to variable strains.

Our solution contributes to the public good by providing a comprehensive dataset on cervical cancer prevalence, enhancing regional population health understanding. The knowledge generated from digitized screenings and AI diagnostics will be valuable resources for public health research. We commit to sharing insights through open-access publications, contributing to the global knowledge base on cervical cancer. This information will be accessible globally, fostering collaboration and supporting efforts to address cervical cancer on a broader scale. Our commitment to knowledge-sharing aligns with the principles of fairness, reasonability, and non-discrimination, making a meaningful contributions to public health.

Our solution is poised to create tangible impact by upgrading cervical cancer screening. The digitized LBC-PAP with AI reduces screening costs, making it accessible to a broader population and high quality results being affordable for everyone. It significantly reduces follow up costs for public health structures. This directly benefits women in underserved and marginalized communities who often face barriers to healthcare. By integrating molecular diagnosis, we ensure accurate HPV typing, and population specific healthcare strategies. This optimizes resource utilization, enhancing the overall impact. Preliminary pilot deployments in India have shown promising results, and our commitment to reducing costs and increasing accessibility aligns with evidence-based approaches to improve health outcomes for women globally.

Over the next 2-3 years, we aim to refine our technology and scale our impact by expanding pilot projects across diverse geographies in India, Singapore and ASEAN. This will provide valuable insights into region-specific needs and streamline the integration of our solution into diverse healthcare systems. Additionally, we plan to establish strategic partnerships with healthcare providers, NGOs, and governmental bodies to facilitate widespread adoption. Leveraging these collaborations, we will scale our solution globally, ensuring accessibility to women in diverse socio-economic contexts. Our commitment to reducing costs and increasing screening accessibility aligns with our vision of transforming cervical cancer screening on a global scale.

We are measuring success against our impact goals through key performance indicators (KPIs) devised from our preliminary experience. These include:

1. Screening Reach: Track the number of women screened, aiming for a annual increase in numbers
2. Cost Reduction: Evaluate the percentage reduction in screening costs compared to current pricing and our own costs over time/events
3. Diagnostic Accuracy: Measure the sensitivity and specificity of our AI-enabled system, ensuring reliable results.
4. Geographical Expansion: Monitor successful integration into new regions, reflecting increased accessibility and number of events conducted for collections

1. Regulatory Approvals: Securing regulatory clearance for medical devices is time-consuming. We plan to expedite the process through proactive engagement with regulatory bodies, leveraging our networks and expertise

2. Financial Constraints: The development and pilots require significant investment. We are seeking funding from grants, collaborations, and partnerships. 

3. Infrastructure Challenges: Majority of the regions lack adequate healthcare infrastructure. We are collaborating with local healthcare providers, NGOs, and government agencies to strengthen healthcare facilities.

4. Cultural Sensitivity: Cultural norms and sensitivities have impacted the adoption. We are conducting culturally tailored awareness campaigns and educational programs and a tailored service offering for complete gynaecological and women health

5. Data Privacy Concerns: We plan to implement robust data encryption, compliance with global data protection regulations, and transparent communication regarding data handling practices.

6. Workforce Training: We are securing medical volunteers, conducting training programs, workshops, and collaborations with medical institutions to equip professionals with the necessary skills.